08/17/2025
Harvard Medical School scientists have made a groundbreaking discovery linking lithium to Alzheimer’s disease treatment. Their research found that lithium levels are significantly lower even in the earliest stages of memory loss. Amyloid-beta plaques, known to cause Alzheimer’s, bind to lithium in the brain, reducing its availability and speeding up the disease’s progression.
This study marks the first time lithium, widely used in psychiatric medicine, has been shown to naturally exist in the brain at important biological levels. In mouse models, lithium depletion caused a rapid buildup of harmful amyloid-beta and tau proteins, increased brain inflammation, and worsened cognitive decline.
The breakthrough came when researchers used lithium orotate, a form of lithium that avoids binding with amyloid-beta plaques. At very low doses, lithium orotate reversed memory loss and other Alzheimer’s-like symptoms in mice without any toxicity. While human trials are still needed, this discovery opens the door to lithium testing as a way to identify people at risk and the potential for targeted lithium supplementation to prevent or even restore cognitive function in dementia patients.
This exciting development could transform the future of Alzheimer’s treatment and prevention, offering new hope to millions worldwide.
